MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer

Guoyan Liu, Yan Sun, Ping Ji, Xia Li, David Cogdell, Da Yang, Brittany C. Parker Kerrigan, Ilya Shmulevich, Kexin Chen, Anil K. Sood, Fengxia Xue, Wei Zhang

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Ovarian carcinoma is the most lethal gynaecological malignancy. Better understanding of the molecular pathogenesis of this disease and effective targeted therapies are needed to improve patient outcomes. MicroRNAs play important roles in cancer progression and have the potential for use as either therapeutic agents or targets. Studies in other cancers have suggested that miR-506 has anti-tumour activity, but its function has yet to be elucidated. We found that deregulation of miR-506 in ovarian carcinoma promotes an aggressive phenotype. Ectopic over-expression of miR-506 in ovarian cancer cells was sufficient to inhibit proliferation and to promote senescence. We also demonstrated that CDK4 and CDK6 are direct targets of miR-506, and that miR-506 can inhibit CDK4/6-FOXM1 signalling, which is activated in the majority of serous ovarian carcinomas. This newly recognized miR-506-CDK4/6-FOXM1 axis provides further insight into the pathogenesis of ovarian carcinoma and identifies a potential novel therapeutic agent.

Original languageEnglish (US)
Pages (from-to)308-318
Number of pages11
JournalJournal of Pathology
Volume233
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Carcinoma
Neoplasms
MicroRNAs
Therapeutics
Phenotype

Keywords

  • FOXM1
  • miR-506
  • ovarian carcinoma
  • proliferation
  • senescence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. / Liu, Guoyan; Sun, Yan; Ji, Ping; Li, Xia; Cogdell, David; Yang, Da; Parker Kerrigan, Brittany C.; Shmulevich, Ilya; Chen, Kexin; Sood, Anil K.; Xue, Fengxia; Zhang, Wei.

In: Journal of Pathology, Vol. 233, No. 3, 2014, p. 308-318.

Research output: Contribution to journalArticle

Liu, G, Sun, Y, Ji, P, Li, X, Cogdell, D, Yang, D, Parker Kerrigan, BC, Shmulevich, I, Chen, K, Sood, AK, Xue, F & Zhang, W 2014, 'MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer', Journal of Pathology, vol. 233, no. 3, pp. 308-318. https://doi.org/10.1002/path.4348
Liu, Guoyan ; Sun, Yan ; Ji, Ping ; Li, Xia ; Cogdell, David ; Yang, Da ; Parker Kerrigan, Brittany C. ; Shmulevich, Ilya ; Chen, Kexin ; Sood, Anil K. ; Xue, Fengxia ; Zhang, Wei. / MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. In: Journal of Pathology. 2014 ; Vol. 233, No. 3. pp. 308-318.
@article{39e6d23e1c4f42b1ad30266537ab8f7d,
title = "MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer",
abstract = "Ovarian carcinoma is the most lethal gynaecological malignancy. Better understanding of the molecular pathogenesis of this disease and effective targeted therapies are needed to improve patient outcomes. MicroRNAs play important roles in cancer progression and have the potential for use as either therapeutic agents or targets. Studies in other cancers have suggested that miR-506 has anti-tumour activity, but its function has yet to be elucidated. We found that deregulation of miR-506 in ovarian carcinoma promotes an aggressive phenotype. Ectopic over-expression of miR-506 in ovarian cancer cells was sufficient to inhibit proliferation and to promote senescence. We also demonstrated that CDK4 and CDK6 are direct targets of miR-506, and that miR-506 can inhibit CDK4/6-FOXM1 signalling, which is activated in the majority of serous ovarian carcinomas. This newly recognized miR-506-CDK4/6-FOXM1 axis provides further insight into the pathogenesis of ovarian carcinoma and identifies a potential novel therapeutic agent.",
keywords = "FOXM1, miR-506, ovarian carcinoma, proliferation, senescence",
author = "Guoyan Liu and Yan Sun and Ping Ji and Xia Li and David Cogdell and Da Yang and {Parker Kerrigan}, {Brittany C.} and Ilya Shmulevich and Kexin Chen and Sood, {Anil K.} and Fengxia Xue and Wei Zhang",
year = "2014",
doi = "10.1002/path.4348",
language = "English (US)",
volume = "233",
pages = "308--318",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer

AU - Liu, Guoyan

AU - Sun, Yan

AU - Ji, Ping

AU - Li, Xia

AU - Cogdell, David

AU - Yang, Da

AU - Parker Kerrigan, Brittany C.

AU - Shmulevich, Ilya

AU - Chen, Kexin

AU - Sood, Anil K.

AU - Xue, Fengxia

AU - Zhang, Wei

PY - 2014

Y1 - 2014

N2 - Ovarian carcinoma is the most lethal gynaecological malignancy. Better understanding of the molecular pathogenesis of this disease and effective targeted therapies are needed to improve patient outcomes. MicroRNAs play important roles in cancer progression and have the potential for use as either therapeutic agents or targets. Studies in other cancers have suggested that miR-506 has anti-tumour activity, but its function has yet to be elucidated. We found that deregulation of miR-506 in ovarian carcinoma promotes an aggressive phenotype. Ectopic over-expression of miR-506 in ovarian cancer cells was sufficient to inhibit proliferation and to promote senescence. We also demonstrated that CDK4 and CDK6 are direct targets of miR-506, and that miR-506 can inhibit CDK4/6-FOXM1 signalling, which is activated in the majority of serous ovarian carcinomas. This newly recognized miR-506-CDK4/6-FOXM1 axis provides further insight into the pathogenesis of ovarian carcinoma and identifies a potential novel therapeutic agent.

AB - Ovarian carcinoma is the most lethal gynaecological malignancy. Better understanding of the molecular pathogenesis of this disease and effective targeted therapies are needed to improve patient outcomes. MicroRNAs play important roles in cancer progression and have the potential for use as either therapeutic agents or targets. Studies in other cancers have suggested that miR-506 has anti-tumour activity, but its function has yet to be elucidated. We found that deregulation of miR-506 in ovarian carcinoma promotes an aggressive phenotype. Ectopic over-expression of miR-506 in ovarian cancer cells was sufficient to inhibit proliferation and to promote senescence. We also demonstrated that CDK4 and CDK6 are direct targets of miR-506, and that miR-506 can inhibit CDK4/6-FOXM1 signalling, which is activated in the majority of serous ovarian carcinomas. This newly recognized miR-506-CDK4/6-FOXM1 axis provides further insight into the pathogenesis of ovarian carcinoma and identifies a potential novel therapeutic agent.

KW - FOXM1

KW - miR-506

KW - ovarian carcinoma

KW - proliferation

KW - senescence

UR - http://www.scopus.com/inward/record.url?scp=84902344416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902344416&partnerID=8YFLogxK

U2 - 10.1002/path.4348

DO - 10.1002/path.4348

M3 - Article

C2 - 24604117

AN - SCOPUS:84902344416

VL - 233

SP - 308

EP - 318

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 3

ER -